Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Metabolomic profile of cancer stem cell‐derived exosomes from patients with malignant melanoma

  • Palacios Ferrer, José Luis
  • García Ortega, María Belén
  • Gallardo Gomez, María
  • García, María Ángel
  • Díaz, Caridad
  • Boulaiz, Houria
  • Valdivia, Javier
  • Jurado, José Miguel
  • Almazán Fernández, Francisco M.
  • Arias Santiago, Salvador
  • Amezcua, Víctor
  • Peinado, Héctor
  • Vicente, Francisca
  • Pérez del Palacio, José
  • Marchal, Juan A.
Malignant melanoma (MM) is the most aggressive and life-threatening form of skin cancer. It is characterized by an extraordinary metastasis capacity and chemotherapy resistance, mainly due to melanoma cancer stem cells (CSCs). To date, there are no suitable clinical diagnostic, prognostic or predictive biomarkers for this neoplasia. Therefore, there is an urgent need for new MM biomarkers that enable early diagnosis and effective disease monitoring. Exosomes represent a novel source of biomarkers since they can be easily isolated from different body fluids. In this work, a primary patient-derived MM cell line enriched in CSCs was characterized by assessing the expression of specific markers and their stem-like properties. Exosomes derived from CSCs and serums from patients with MM were characterized, and their metabolomic profile was analysed by high-resolution mass spectrometry (HRMS) following an untargeted approach and applying univariate and multivariate statistical analyses. The aim of this study was to search potential biomarkers for the diagnosis of this disease. Our results showed significant metabolomic differences in exosomes derived from MM CSCs compared with those from differentiated tumour cells and also in serum-derived exosomes from patients with MM compared to those from healthy controls. Interestingly, we identified similarities between structural lipids differentially expressed in CSC-derived exosomes and those derived from patients with MM such as the glycerophosphocholine PC 16:0/0:0. To our knowledge, this is the first metabolomic-based study aimed at characterizing exosomes derived from melanoma CSCs and patients' serum in order to identify potential biomarkers for MM diagnosis. We conclude that metabolomic characterization of CSC-derived exosomes sets an open door to the discovery of clinically useful biomarkers in this neoplasia, Ministerio de Ciencia, Innovación y Universidades | Ref. FPU15/03682, Ministerio de Ciencia, Innovación y Universidades | Ref. FPU15/02350, Ministerio de Ciencia, Innovación y Universidades | Ref. MAT2015-62644.C2.2.R, Ministerio de Ciencia, Innovación y Universidades | Ref. RTI2018-101309-BC2, Instituto de Salud Carlos III | Ref. PIE16-00045, Junta de Andalucía | Ref. UCE-PP2017-3, European Commission | Ref. SOMM17/6109/UGR, Universidad de Granada | Ref. CMC-CTS963
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Betulinic acid hydroxamate prevents colonic inflammation and fibrosis in murine models of inflammatory bowel disease

  • Prados, María E.
  • García-Martín, Adela
  • Unciti‑Broceta, Juan D.
  • Palomares, Belén
  • Collado, Juan A.
  • Minassi, Alberto
  • Calzado Canale, Marco Antonio
  • Appendino, Giovanni
  • Muñoz, Eduardo
Embargado hasta 01-01-2100, Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) and is defined as an excessive accumulation of scar tissue in the intestinal wall. Intestinal fibrosis occurs in both forms of IBD: ulcerative colitis and Crohn’s disease. Small-molecule inhibitors targeting hypoxia-inducing factor (HIF) prolyl-hydroxylases are promising for the development of novel antifibrotic therapies in IBD. Herein, we evaluated the therapeutic efficacy of hydroxamate of betulinic acid (BHA), a hypoxia mimetic derivative of betulinic acid, against IBD in vitro and in vivo. We showed that BAH (5–20 μM) dose-dependently enhanced collagen gel contraction and activated the HIF pathway in NIH-3T3 fibroblasts; BAH treatment also prevented the loss of trans-epithelial electrical resistance induced by proinflammatory cytokines in Caco-2 cells. In two different murine models (TNBS- and DSS-induced IBD) that cause colon fibrosis, oral administration of BAH (20, 50 mg/kg·d, for 17 days) prevented colon inflammation and fibrosis, as detected using immunohistochemistry and qPCR assays. BAH-treated animals showed a significant reduction of fibrotic markers (Tnc, Col1a2, Col3a1, Timp-1, α-SMA) and inflammatory markers (F4/80+, CD3+, Il-1β, Ccl3) in colon tissue, as well as an improvement in epithelial barrier integrity and wound healing. BHA displayed promising oral bioavailability, no significant activity against a panel of 68 potential pharmacological targets and was devoid of genotoxicity and cardiotoxicity. Taken together, our results provide evidence that oral administration of BAH can alleviate colon inflammation and colitis-associated fibrosis, identifying the enhancement of colon barrier integrity as a possible mechanism of action, and providing a solid rationale for additional clinical studies